Dissolution Similarity Requirements: How Similar or Dissimilar Are the Global Regulatory Expectations?

Area of Science:

• Pharmaceutical Sciences
• Regulatory Science
• Drug Development

Background:

• The model-independent similarity factor (f2) approach is used internationally to compare drug dissolution profiles.
• Divergent global regulatory expectations exist for demonstrating dissolution similarity.
• Current approaches can lead to increased costs and delayed access to medicines.

Purpose of the Study:

• To compare and contrast international expectations for the model-independent similarity factor approach in dissolution profile comparison.
• To highlight divergent global regulatory requirements for dissolution similarity.
• To identify the impact of these differences on pharmaceutical manufacturing and patient access.

Main Methods:

• Comparative analysis of international regulatory guidelines and scientific literature.
• Assessment of the model-independent similarity factor approach in dissolution testing.
• Evaluation of the implications of divergent requirements on cost, innovation, and patient access.

Main Results:

• Significant global divergence in regulatory requirements for dissolution profile similarity was identified.
• Current varied expectations necessitate customized experiments, increasing costs and regulatory burden.
• These differences hinder science- and risk-based approaches and potentially delay medication access.

Conclusions:

• Comparative assessment of regulatory differences in dissolution testing is crucial.
• Harmonization of global regulatory expectations can reduce non-scientifically justified experiments.
• Collaboration between regulatory authorities and industry is needed to foster harmonization and improve drug accessibility.